Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
2021-2040 of 2,120 trials

Chronic Limb-Threatening Ischemia: Bone Marrow Cell Therapy

We are comparing a new treatment using your own bone marrow cells with standard care for diabetic patients with severe circulation problems. The goal is to see if this therapy improves tissue oxygen levels and overall health.

Diabetic Foot SyndromeLower Limb Ischemia6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCardiologyEndocrinologyInternal MedicineOrthopedics and Traumatology

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyOrthopedics and Traumatology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Liver Surgery: Blood Clot Prevention Study

We are comparing two methods of preventing blood clots in patients undergoing liver resection. The goal is to find out which method is safer and more effective in reducing clot risks.

Liver SurgeryMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematologyOrthopedics and Traumatology

Hidradenitis Suppurativa: Tibulizumab Study

We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.

Hidradenitis Suppurativa6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

High-Dose Influenza Vaccine for Adults 60 and Older

We are studying a new high-dose flu vaccine to see if it provides better immune protection than a standard vaccine for adults aged 60 and above. The trial will also assess the safety of this new vaccine.

Influenza Immunization1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Chronic Rhinosinusitis with Nasal Polyps: Tapering Biologics

We are studying whether patients with stable chronic rhinosinusitis can safely reduce their biologic medication dosage after a year. This trial compares the effects of Mepolizumab and Dupilumab on disease control.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Metastatic Uveal Melanoma: Liver Radiotherapy with Tebentafusp

We are studying if adding liver-directed radiotherapy to the standard treatment helps patients with metastatic uveal melanoma live longer and stay on treatment longer. This trial also looks at how the body responds to the combination therapy.

Metastatic Uveal MelanomaEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Gastric Cancer: Zolbetuximab with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for adults with advanced gastric cancer to see if it works better than standard therapies. This trial is for patients with specific tumor markers.

Gastric CancerMetastatic Gastric CancerGastroesophageal Junction AdenocarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Rezafungin for Fungal Infections in Critically Ill Patients

We are studying how Rezafungin levels change in patients on ECMO, a life-support treatment. This research aims to understand its effectiveness and any potential side effects.

Invasive Candidiasis>2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Atopic Dermatitis: Long-term Study of APG777

We are examining the long-term safety and effectiveness of APG777 in patients with moderate-to-severe atopic dermatitis who have already used this treatment. The goal is to see how well it works over time and if it remains safe.

Atopic DermatitisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Chronic Heart Failure: Vitamin D and Oral Iron Study

We are studying whether vitamin D combined with oral iron can improve symptoms in patients with chronic heart failure and iron deficiency. This trial compares it to standard intravenous iron treatment to see which is more effective.

Chronic Heart FailureIron Deficiency3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Type 1 Diabetes: Once-Weekly Insulin Icodec vs. Daily Insulin Glargine

We are studying whether a new once-weekly insulin can help adults with type 1 diabetes manage their blood sugar levels as well as the standard daily insulin. This trial will also look at safety and patient experiences.

Type 1 Diabetes6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesDiabetologyEndocrinology

Botox for Hidradenitis Suppurativa Treatment

We are studying whether Botox can help reduce symptoms in patients with Hidradenitis Suppurativa. This trial will assess changes in skin condition and patient satisfaction over several months.

Hidradenitis SuppurativaMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesAllergologyDermatology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology